Nvidia (NASDAQ: NVDA) has been one of the best-performing stocks in recent years, with its price up more than 1,000% since ...

Celcuity's stock surged over 112% in premarket trading following positive Phase 3 trial results for its breast cancer treatment, marking a potential breakthrough in targeted cancer therapy.

Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called ...

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

Shona also quoted doctor Tom Hildebrandt, who said he was seeing an increase in patients with eating disorders taking ...

FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Image source: Getty Images. As such, look out for the phase 2 results later in the year. In addition, note that Novo Nordisk has submitted to the FDA for approval of an oral formulation of Wegovy ...